Breaking News Instant updates and real-time market news.

PBYI

Puma Biotechnology

$42.19

-0.5 (-1.17%)

, RHHBY

Roche

$0.00

(0.00%)

10:20
10/15/18
10/15
10:20
10/15/18
10:20

Roche breast cancer data could pressure Puma shares, says RBC Capital

RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.

PBYI

Puma Biotechnology

$42.19

-0.5 (-1.17%)

RHHBY

Roche

$0.00

(0.00%)

  • 16

    Oct

  • 19

    Oct

  • 07

    Nov

  • 24

    Dec

PBYI Puma Biotechnology
$42.19

-0.5 (-1.17%)

09/17/18
GSCO
09/17/18
INITIATION
Target $42
GSCO
Sell
Puma Biotechnology initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Paul Choi started Puma Biotechnology with a Sell rating and $42 price target. The analyst sees see 11% downside in the shares versus 20% upside on average for his coverage universe. While the company's Nerlynx launch in the extended adjuvant setting in HER2+ breast cancer has gone well to date, channel checks and analysis suggest that consensus estimates are overly optimistic with respect to patient adds in this setting, Choi tells investors in a research note. The analyst initiated coverage of the smid-cap biotech sector with a Neutral coverage view. He views sector fundamentals as healthy but says high valuations temper his enthusiasm.
09/17/18
GUGG
09/17/18
INITIATION
Target $85
GUGG
Buy
Puma Biotechnology initiated with a Buy at Guggenheim
Target $85.
09/18/18
09/18/18
NO CHANGE
Target $151

Buy
Physician survey supports Puma's Nerlynx hitting $1B in sales, says Citi
Citi analyst Yigal Nochomovitz says his 100-physician survey of U.S. oncologists supports his "long-standing bull thesis" that Puma Biotechnology's Nerlynx is positioned to be a billion-dollar drug. Continued fundamental upside to the launch should limit investor concerns around a "stalled" launch that has been pressuring the stock, Nochomovitz tells investors in a research note. The survey indicates that one-in-four adjuvant Herceptin patients are expected to receive Nerlynx. This provides "substantive validation" that 20%-25% of Herceptin completers are high-risk and thus likely Nerlynx patients, Nochomovitz contends. The analyst lowered his price target for Puma shares to $151 from $164 and keeps a Buy rating on the name.
10/01/18
CANT
10/01/18
INITIATION
Target $75
CANT
Overweight
Puma Biotechnology initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Puma Biotechnology with an Overweight rating and $75 price target.
RHHBY Roche
$0.00

(0.00%)

09/21/18
PIPR
09/21/18
NO CHANGE
Target $400
PIPR
Overweight
Biogen upcoming BIIB098 data an overlooked catalyst, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond believes investor sentiment on Biogen (BIIB) overlooks the H2H tolerability data for BIIB098 versus Tecfidera coming in the first half of 2018 Though BIIB098 is largely discounted as an intellectual property play "or worse," the readout, if positive, may be an important catalyst ahead of FDA approval in Q4 of 2019, Raymond tells investors in a research note. He suspects that if BIIB098 shows meaningful tolerability improvement over Tecfidera, "docs will likely take notice." Further, Raymond's new neurologist survey indicates that while the launch trends of Roche's (RHHBY) multiple sclerosis drugOcrevus "appear to be improving," other share trends, including those for Tecfidera and Tysabri, "remain stable." The analyst keeps an Overweight rating on Biogen with a $400 price target.
10/03/18
PIPR
10/03/18
NO CHANGE
PIPR
Overweight
PTC, Roche data add uncertainty to Biogen drug outlook, says Piper Jaffray
The risdiplam spinal muscular atrophy data released this morning by PTC Therapeutic (PTCT) and Roche (RHHBY) stack up fairly well to Biogen's (BIIB) Spinraza clinical data, Piper Jaffray analyst Christopher Raymond tells investors in a research note. Even taking into account all of the usual caveats regarding cross-trial comparisons, risdiplam is shaping up well compared to Spinraza, the analyst contends. He sees the new data as adding uncertainty to the Spinraza trajectory. Nonetheless, Raymond keeps an Overweight rating on shares of Biogen. The analyst made no changes to his Biogen model, but he admits risdiplam, if the data holds up, may impact Spinraza's ultimate market potential. Biogen in midday trading is up 2% to $351.41.
10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.

TODAY'S FREE FLY STORIES

UUUU

Energy Fuels

$3.19

0.04 (1.27%)

14:30
03/25/19
03/25
14:30
03/25/19
14:30
Options
Trader scoops up nearly 2K lotto ticket calls in Energy Fuels »

Trader scoops up nearly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$71.09

0.03 (0.04%)

14:28
03/25/19
03/25
14:28
03/25/19
14:28
Hot Stocks
Prologis CLO sells over 16,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

CRSP

Crispr Therapeutics

$33.86

-1.73 (-4.86%)

14:28
03/25/19
03/25
14:28
03/25/19
14:28
Conference/Events
Crispr Therapeutics management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Apr

  • 08

    Apr

IONS

Ionis Pharmaceuticals

$78.76

-0.24 (-0.30%)

14:27
03/25/19
03/25
14:27
03/25/19
14:27
Conference/Events
Ionis Pharmaceuticals management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Apr

OESX

Orion Energy

$0.91

0.017 (1.90%)

14:25
03/25/19
03/25
14:25
03/25/19
14:25
Hot Stocks
Orion's Altschaefl says new products coming in April, May »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

AXSM

Axsome Therapeutics

$15.30

2.3 (17.69%)

14:25
03/25/19
03/25
14:25
03/25/19
14:25
Options
Axsome Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDAY

Workday

$189.95

-1.05 (-0.55%)

14:21
03/25/19
03/25
14:21
03/25/19
14:21
Hot Stocks
Workday says CIO McKenzie departing in April, Rhodes joining as new CIO »

In a blog post, Workday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
03/25/19
03/25
14:17
03/25/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
03/25/19
03/25
14:16
03/25/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$415.08

-1.92 (-0.46%)

, APO

Apollo Global

$27.93

-0.07 (-0.25%)

14:10
03/25/19
03/25
14:10
03/25/19
14:10
Periodicals
BlackRock, Varde to make rival offers for Banca Carige, Reuters reports »

Varde Partners and…

BLK

BlackRock

$415.08

-1.92 (-0.46%)

APO

Apollo Global

$27.93

-0.07 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

F

Ford

$8.53

0.005 (0.06%)

14:10
03/25/19
03/25
14:10
03/25/19
14:10
Options
Ford puts lead calls 6:1 »

Ford puts lead calls 6:1.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

ASND

Ascendis Pharma

$115.50

-3.71 (-3.11%)

14:07
03/25/19
03/25
14:07
03/25/19
14:07
Hot Stocks
Ascendis Pharma announces results of study of hypoparathyroidism at ENDO 2019 »

Ascendis Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.31

-2.8 (-1.47%)

14:07
03/25/19
03/25
14:07
03/25/19
14:07
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple says Apple TV+ will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

IP

International Paper

$44.43

0.03 (0.07%)

14:05
03/25/19
03/25
14:05
03/25/19
14:05
Options
International Paper call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.74

-2.37 (-1.24%)

14:05
03/25/19
03/25
14:05
03/25/19
14:05
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple CEO Tim Cook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

14:05
03/25/19
03/25
14:05
03/25/19
14:05
General news
Treasury Action: the $40 B 2-year note sale Tuesday »

Treasury Action: the $40…

AAPL

Apple

$188.48

-2.63 (-1.38%)

, ROKU

Roku

$67.67

4.15 (6.53%)

14:03
03/25/19
03/25
14:03
03/25/19
14:03
Hot Stocks
Breaking Hot Stocks news story on Apple, Roku, Amazon.com »

Apple bringing Apple TV…

AAPL

Apple

$188.48

-2.63 (-1.38%)

ROKU

Roku

$67.67

4.15 (6.53%)

AMZN

Amazon.com

$1,762.35

-2.61 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 29

    Mar

  • 04

    Apr

  • 03

    Jun

AAPL

Apple

$188.51

-2.6 (-1.36%)

, SNE

Sony

$42.00

-0.09 (-0.21%)

14:03
03/25/19
03/25
14:03
03/25/19
14:03
Hot Stocks
Breaking Hot Stocks news story on Apple, Sony »

Apple bringing Apple TV…

AAPL

Apple

$188.51

-2.6 (-1.36%)

SNE

Sony

$42.00

-0.09 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

OESX

Orion Energy

$0.91

0.017 (1.90%)

, TM

Toyota

$120.19

0.39 (0.33%)

13:57
03/25/19
03/25
13:57
03/25/19
13:57
Hot Stocks
Orion CEO sees $11M Letter of Intent as 'very significant win' »

In an exclusive interview…

OESX

Orion Energy

$0.91

0.017 (1.90%)

TM

Toyota

$120.19

0.39 (0.33%)

F

Ford

$8.55

0.03 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

ANF

Abercrombie & Fitch

$25.25

0.73 (2.98%)

13:55
03/25/19
03/25
13:55
03/25/19
13:55
Options
Abercrombie & Fitch put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.61

-2.5 (-1.31%)

13:54
03/25/19
03/25
13:54
03/25/19
13:54
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple announces Apple TV…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.61

-2.5 (-1.31%)

13:53
03/25/19
03/25
13:53
03/25/19
13:53
Hot Stocks
Apple introduces Apple Arcade game subscription service »

Apple announced Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.60

-2.51 (-1.31%)

13:51
03/25/19
03/25
13:51
03/25/19
13:51
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade pricing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.60

-2.51 (-1.31%)

13:50
03/25/19
03/25
13:50
03/25/19
13:50
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.08

-3.03 (-1.59%)

13:48
03/25/19
03/25
13:48
03/25/19
13:48
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.